Antibody Pipeline – Overview

MorphoSys commercializes its proprietary HuCAL technology by developing antibodies for use as therapeutic antibodies or reagents for target research. The Company has been successful in establishing a variety of different partnerships as a means of validating and commercializing its technologies.

In its therapeutic antibody collaborations, MorphoSys produces optimized human antibodies for its partners according to their specifications. MorphoSys generates and optimizes the antibodies, whereas the partner is responsible for pre-clinical and clinical development. Moreover, MorphoSys has developed proprietary therapeutic antibody candidates in the area of inflammation and oncology. These candidates are available for future partnering.

The Company’s product pipeline comprises both partnered and proprietary antibody therapeutic development programs and can be graphically depicted as below: